AR093126A1 - Formulaciones de liberacion modificada para oprozomib - Google Patents
Formulaciones de liberacion modificada para oprozomibInfo
- Publication number
- AR093126A1 AR093126A1 ARP130103868A ARP130103868A AR093126A1 AR 093126 A1 AR093126 A1 AR 093126A1 AR P130103868 A ARP130103868 A AR P130103868A AR P130103868 A ARP130103868 A AR P130103868A AR 093126 A1 AR093126 A1 AR 093126A1
- Authority
- AR
- Argentina
- Prior art keywords
- oprozomib
- release formulations
- modified release
- pharmaceutically acceptable
- hplc
- Prior art date
Links
- 108010064641 ONX 0912 Proteins 0.000 title abstract 3
- SWZXEVABPLUDIO-WSZYKNRRSA-N n-[(2s)-3-methoxy-1-[[(2s)-3-methoxy-1-[[(2s)-1-[(2r)-2-methyloxiran-2-yl]-1-oxo-3-phenylpropan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]-2-methyl-1,3-thiazole-5-carboxamide Chemical compound N([C@@H](COC)C(=O)N[C@@H](COC)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)[C@]1(C)OC1)C(=O)C1=CN=C(C)S1 SWZXEVABPLUDIO-WSZYKNRRSA-N 0.000 title abstract 3
- 229950005750 oprozomib Drugs 0.000 title abstract 3
- 239000000203 mixture Substances 0.000 title abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 238000004090 dissolution Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 238000004128 high performance liquid chromatography Methods 0.000 abstract 1
- 230000002035 prolonged effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/06—Tripeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Diabetes (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Otolaryngology (AREA)
- Psychiatry (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261717975P | 2012-10-24 | 2012-10-24 | |
| US201261721244P | 2012-11-01 | 2012-11-01 | |
| US201361793087P | 2013-03-15 | 2013-03-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR093126A1 true AR093126A1 (es) | 2015-05-20 |
Family
ID=50485877
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP130103868A AR093126A1 (es) | 2012-10-24 | 2013-10-24 | Formulaciones de liberacion modificada para oprozomib |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US9295708B2 (instruction) |
| EP (1) | EP2912025A4 (instruction) |
| JP (1) | JP6505604B2 (instruction) |
| KR (1) | KR20150070406A (instruction) |
| CN (1) | CN104968650A (instruction) |
| AP (1) | AP3681A (instruction) |
| AR (1) | AR093126A1 (instruction) |
| AU (1) | AU2013334258A1 (instruction) |
| BR (1) | BR112015008572A2 (instruction) |
| CA (1) | CA2888039A1 (instruction) |
| CL (1) | CL2015001085A1 (instruction) |
| CR (1) | CR20150266A (instruction) |
| EA (1) | EA201590797A1 (instruction) |
| HK (2) | HK1215709A1 (instruction) |
| IL (1) | IL238244A0 (instruction) |
| IN (1) | IN2015DN03921A (instruction) |
| MX (1) | MX2015005069A (instruction) |
| PE (1) | PE20151051A1 (instruction) |
| PH (1) | PH12015500823A1 (instruction) |
| SG (1) | SG11201502849XA (instruction) |
| TN (1) | TN2015000135A1 (instruction) |
| TW (1) | TW201422255A (instruction) |
| UY (1) | UY35091A (instruction) |
| WO (1) | WO2014066681A1 (instruction) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI568722B (zh) | 2012-06-15 | 2017-02-01 | 葛蘭馬克製藥公司 | 作爲ｍＰＧＥＳ－１抑制劑之三唑酮化合物 |
| AU2016278846B2 (en) * | 2015-06-19 | 2021-08-05 | Biotie Therapies, Inc. | Controlled-release tozadenant formulations |
| CN105949279A (zh) * | 2016-04-27 | 2016-09-21 | 浙江大学 | 蛋白酶体抑制剂Oprozomib及其类似物的制备方法 |
| CN109641860B (zh) | 2016-06-29 | 2024-05-28 | 科智生命科学公司 | 制备肽环氧酮免疫蛋白酶体抑制剂和其前体的方法 |
| US20180078532A1 (en) * | 2016-09-21 | 2018-03-22 | Amgen Inc. | Immediate release formulations for oprozomib |
| US20180161279A1 (en) * | 2016-12-14 | 2018-06-14 | Amgen Inc. | Gastro-retentive modified release dosage forms for oprozomib and process to make thereof |
| EP3694878A1 (en) | 2017-09-14 | 2020-08-19 | GlaxoSmithKline Intellectual Property Development Limited | Combination treatment for cancer |
| CN110357940A (zh) * | 2019-08-02 | 2019-10-22 | 苏州艾和医药科技有限公司 | 奥普佐米合成工艺研究 |
| KR20250008774A (ko) | 2022-05-11 | 2025-01-15 | 셀진 코포레이션 | T 세포 요법 및 그의 생산과 관련된 방법 및 용도 |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5126145A (en) * | 1989-04-13 | 1992-06-30 | Upsher Smith Laboratories Inc | Controlled release tablet containing water soluble medicament |
| JPH06199657A (ja) * | 1992-12-10 | 1994-07-19 | Sumitomo Pharmaceut Co Ltd | 徐放性製剤 |
| WO1998010779A1 (en) | 1996-09-13 | 1998-03-19 | New York University | Method for treating parasitic diseases with proteasome inhibitors |
| JP4748839B2 (ja) * | 1999-03-25 | 2011-08-17 | 大塚製薬株式会社 | シロスタゾール製剤 |
| DE60221642T3 (de) * | 2001-02-12 | 2017-10-26 | Wyeth LLC (n.d.Ges.d. Staates Delaware) | O-desmethyl-venlafaxine succinat salz |
| US8119154B2 (en) * | 2004-04-30 | 2012-02-21 | Allergan, Inc. | Sustained release intraocular implants and related methods |
| MY145757A (en) * | 2005-11-09 | 2012-04-13 | Proteolix Inc | Compounds for enzyme inhibition |
| US20100172988A1 (en) * | 2006-01-10 | 2010-07-08 | Kissei Pharmaceutical Co., Ltd. | Sustained release preparation and method for production thereof |
| WO2008140782A2 (en) | 2007-05-10 | 2008-11-20 | Proteolix, Inc. | Compounds for enzyme inhibition |
| CL2008002966A1 (es) * | 2007-10-04 | 2010-06-25 | Onyx Therapeutics Inc | Compuesto tetrapeptido ceto-epoxido cristalino; sal citrato cristalina del compuesto; metodos de preparacion; compuesto intermediario cristalino; metodo de preparacion; y uso para tratar cancer, enfermedad autoinmune, afeccion relacionada con trasplante, enfermedad neurodegenerativa, afeccion asociada con fibrosis, entre otros. |
| AR075899A1 (es) * | 2009-03-20 | 2011-05-04 | Onyx Therapeutics Inc | Tripeptidos epoxicetonas cristalinos inhibidores de proteasa |
-
2013
- 2013-10-22 UY UY0001035091A patent/UY35091A/es not_active Application Discontinuation
- 2013-10-22 TW TW102138163A patent/TW201422255A/zh unknown
- 2013-10-24 CA CA2888039A patent/CA2888039A1/en not_active Abandoned
- 2013-10-24 KR KR1020157013739A patent/KR20150070406A/ko not_active Withdrawn
- 2013-10-24 MX MX2015005069A patent/MX2015005069A/es unknown
- 2013-10-24 EP EP13849834.0A patent/EP2912025A4/en not_active Withdrawn
- 2013-10-24 CN CN201380067772.0A patent/CN104968650A/zh active Pending
- 2013-10-24 HK HK16103699.0A patent/HK1215709A1/zh unknown
- 2013-10-24 AR ARP130103868A patent/AR093126A1/es unknown
- 2013-10-24 WO PCT/US2013/066679 patent/WO2014066681A1/en active Application Filing
- 2013-10-24 JP JP2015539810A patent/JP6505604B2/ja not_active Expired - Fee Related
- 2013-10-24 EA EA201590797A patent/EA201590797A1/ru unknown
- 2013-10-24 AU AU2013334258A patent/AU2013334258A1/en not_active Abandoned
- 2013-10-24 HK HK15108858.7A patent/HK1208222A1/xx unknown
- 2013-10-24 IN IN3921DEN2015 patent/IN2015DN03921A/en unknown
- 2013-10-24 PE PE2015000537A patent/PE20151051A1/es not_active Application Discontinuation
- 2013-10-24 BR BR112015008572A patent/BR112015008572A2/pt not_active Application Discontinuation
- 2013-10-24 SG SG11201502849XA patent/SG11201502849XA/en unknown
- 2013-10-24 AP AP2015008387A patent/AP3681A/xx active
- 2013-10-24 US US14/062,759 patent/US9295708B2/en not_active Expired - Fee Related
-
2015
- 2015-04-08 TN TNP2015000135A patent/TN2015000135A1/fr unknown
- 2015-04-12 IL IL238244A patent/IL238244A0/en unknown
- 2015-04-15 PH PH12015500823A patent/PH12015500823A1/en unknown
- 2015-04-24 CL CL2015001085A patent/CL2015001085A1/es unknown
- 2015-05-20 CR CR20150266A patent/CR20150266A/es unknown
-
2016
- 2016-01-28 US US15/008,634 patent/US20160213610A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| HK1215709A1 (zh) | 2016-09-09 |
| IL238244A0 (en) | 2015-06-30 |
| US20140113855A1 (en) | 2014-04-24 |
| BR112015008572A2 (pt) | 2017-07-04 |
| EA201590797A1 (ru) | 2016-02-29 |
| US9295708B2 (en) | 2016-03-29 |
| KR20150070406A (ko) | 2015-06-24 |
| AP3681A (en) | 2016-04-19 |
| WO2014066681A1 (en) | 2014-05-01 |
| HK1208222A1 (en) | 2016-02-26 |
| CR20150266A (es) | 2015-08-14 |
| JP6505604B2 (ja) | 2019-04-24 |
| US20160213610A1 (en) | 2016-07-28 |
| AP2015008387A0 (en) | 2015-04-30 |
| PH12015500823A1 (en) | 2015-06-22 |
| IN2015DN03921A (instruction) | 2015-10-02 |
| JP2015535255A (ja) | 2015-12-10 |
| PE20151051A1 (es) | 2015-08-03 |
| SG11201502849XA (en) | 2015-05-28 |
| CL2015001085A1 (es) | 2015-08-28 |
| UY35091A (es) | 2014-05-30 |
| AU2013334258A1 (en) | 2015-04-30 |
| CA2888039A1 (en) | 2014-05-01 |
| EP2912025A1 (en) | 2015-09-02 |
| EP2912025A4 (en) | 2016-06-08 |
| TN2015000135A1 (en) | 2016-10-03 |
| MX2015005069A (es) | 2015-07-17 |
| TW201422255A (zh) | 2014-06-16 |
| CN104968650A (zh) | 2015-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR093126A1 (es) | Formulaciones de liberacion modificada para oprozomib | |
| ECSP21072161A (es) | Composiciones de liberación retardada de linaclotida | |
| CR20180232A (es) | Macrociclos peptídicos contra acinetobacter baumannii | |
| DOP2014000204A (es) | Compuestos de heterociclilo como inhibidores de mek | |
| CL2017000902A1 (es) | Dihidropirrolopiridinas inhibidoras de ror-gamma | |
| CL2017002727A1 (es) | Composiciones de ácido obeticólico y métodos de uso | |
| CU20180152A7 (es) | Pirimidin-2-ilamino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| CL2016000882A1 (es) | Composiciones de arni contra el componente c5 del complemento y métodos para su uso (divisional de sol. n°2710-15). | |
| NI201600018A (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b. | |
| MX376122B (es) | Composiciones de plinabulina. | |
| DOP2013000239A (es) | Derivados de ácido 3-fenilpropiónico ramificados y su uso. | |
| CO7121351A2 (es) | Composiciones y métodos para inhibir la expresión del gen alas1 | |
| MX2011010415A (es) | Formulaciones farmaceuticas que comprenden derivados de nitrocatecol y metodos para hacer las mismas. | |
| DOP2011000382A (es) | Sulfonamidas heterociclicas, usos y composiciones farmaceuticas de las mismas | |
| DOP2016000253A (es) | Nuevos compuestos | |
| BR112015011430A2 (pt) | composição para liberação imediata e prolongada | |
| BR112012033755A2 (pt) | composições e métodos antissépticos estáveis | |
| CR20150419A (es) | Derivados sustituidos del ácido bisfenil butanóico fosfónico como inhibidores de la nep | |
| PE20151979A1 (es) | Compuestos quimicos | |
| MX2016011290A (es) | Composiciones de ester de colina de acido lipoico y metodos de uso. | |
| MX2015016971A (es) | Formulacion que comprende un agente hipolipidemico. | |
| MX340983B (es) | Composiciones farmaceuticas y nutraceuticas de acido abscisico. | |
| BR112014014877A2 (pt) | derivados da 1,5-naftiridina e inibidores do melk contendo os mesmos | |
| CR20130318A (es) | Nuevos compuestos de benzodioxol-piperazina | |
| DOP2018000049A (es) | Compuestos para uso en aplicaciones antibacterianas |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |